Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis.

Blood - 12 Mar 2020

Zhang Xiaotian, Wang Xinyu, Wang Xue Qing David, Su Jianzhong, Putluri Nagireddy, Zhou Ting, Qu Ying, Jeong Mira, Guzman Anna, Rosas Carina, Huang Yun, Sreekumar Arun, Li Wei, Goodell Margaret A

Abstract excerpt

Mutations in the epigenetic regulators DNMT3A and IDH1/2 co-occur in patients with acute myeloid leukemia and lymphoma. In this study, these 2 epigenetic mutations cooperated to induce leukemia. Leukemia-initiating cells from Dnmt3a-/- mice that express an IDH2 neomorphic mutant have a megakaryocyte-erythroid progenitor-like immunophenotype, activate a stem-cell-like gene signature, and repress differentiated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Immunoprecipitation Sequencing
Share to DNA (Cytosine-5-)-Methyltransferases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methyltransferase 3A

Share to Hematologic Neoplasms

Share to Hematopoiesis

Share to Isocitrate Dehydrogenase

Share to Metabolome

Share to Metabolomics

Source

Open in PubMed Open full text

Identifiers

PMID: 31932841
DOI: 10.1182/blood.2019003330
PMCID: PMC7068035

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis.PMID 31932841Read ↗

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.Semantic proximity Read ↗

Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation.Semantic proximity Read ↗

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells.Semantic proximity Read ↗

AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in VivoSemantic proximity Read ↗

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.Semantic proximity Read ↗

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.Semantic proximity Read ↗

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.Semantic proximity Read ↗

IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid LeukemiaSemantic proximity Read ↗

Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs.Semantic proximity Read ↗

Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.Semantic proximity Read ↗

Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.